EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?

Karen M Clements, Gerson Peltz, Douglas E Faries, Kathleen Lang, Joshua Nyambose, Craig C Earle, Katherine P Sugarman, Douglas C A Taylor, David Thompson, Martin D Marciniak

Chemotherapy Research and Practice · 2010

DOI: 10.1155/2010/524629 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemotherapy Research and Practice, 2010. Verfasst von Karen M Clements und 9 weiteren Autor:innen. Beteiligte Einrichtung: i3 Innovus, Medford, MA 02155, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Eli Lilly and Company.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of patients ( N = 2 ,644) with stage IIIB/IV NSCLC who received first-line cisplatin/carboplatin plus gemcitabine (C/C+G) and cisplatin/carboplatin plus a taxane (C/C+T) identified retrospectively in the SEER cancer registry (1997–2002). Patients with squamous and nonsquamous cell carcinoma survived 8.5 months and 8.1 months, respectively ( P = .018 ). No statistically significant difference was observed in survival between C/C+G and C/C+T in both histologies. Adjusting for clinical and demographic characteristics, the effect of treatment regimen on survival did not differ by histology ( P for interaction = .257 ). There was no statistically significant difference in hazard of death by histology in both groups. These results contrast the predictive role of histology and improved survival outcomes observed for cisplatin-pemetrexed regimens in advanced nonsquamous NSCLC.

Autor:innen und Institutionen

  • i3 Innovus, Medford, MA 02155, USA.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Clements, K. M., Peltz, G., Faries, D. E., Lang, K., Nyambose, J., Earle, C. C., Sugarman, K. P., Taylor, D. C., Thompson, D., & Marciniak, M. D. (2010). Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?. Chemotherapy Research and Practice. https://doi.org/10.1155/2010/524629

Vancouver

Clements KM, Peltz G, Faries DE, Lang K, Nyambose J, Earle CC, et al. Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?. Chemotherapy Research and Practice. 2010. doi:10.1155/2010/524629

BibTeX
@article{Clements2010,
  author = {Clements, Karen M and Peltz, Gerson and Faries, Douglas E and Lang, Kathleen and Nyambose, Joshua and Earle, Craig C and Sugarman, Katherine P and Taylor, Douglas C A and Thompson, David and Marciniak, Martin D},
  title = {Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?},
  journal = {Chemotherapy Research and Practice},
  year = {2010},
  doi = {10.1155/2010/524629}
}
Kostenlos starten →